Translating Cancer Advances into Real-World Survivorship
Each year, oncology gathers around the latest breakthroughs: new therapies, biomarkers, technologies, data. At the American Society of Clinical Oncology (ASCO) Annual Meeting, this year’s presidential theme, “The Science and Practice of Translation: Improving Cancer Outcomes Worldwide,” highlights an important truth: discovery alone is not enough. Progress only matters when it reaches patients in ways that meaningfully improve their lives.
That same principle sits at the heart of National Cancer Survivors Month, which takes place every June. Survivorship is not simply about living longer. It is about what happens after diagnosis, after treatment, and long after the clinical milestones have been checked off.
Today, there are millions of cancer survivors worldwide, but survivorship remains deeply uneven. Many patients complete treatment only to face new barriers: long-term toxicities, financial strain, fragmented follow-up care, mental health challenges, infertility concerns, chronic symptoms, or difficulty returning to work and daily life.
The gap between innovation and implementation is especially visible in survivorship care. Oncology has become increasingly effective at helping patients live longer, but health systems worldwide have not evolved at the same pace to support what comes after treatment. Care remains fragmented, inconsistently resourced, and disconnected from the settings where patients actually live their lives.
In many ways, oncology is entering a new phase. The challenge is no longer only how to treat cancer, but how to support growing survivor populations across a highly complex global landscape. Even in high-resource settings, survivorship programs remain inaccessible outside major academic centers. In low-resource settings, basic infrastructure like rehabilitation, psychosocial support, and care navigation barely exist at all.
This is where translation becomes a structural mandate rather than a scientific concept.
In oncology, translation is often framed as moving discoveries from bench to bedside. But real translation also means ensuring that advances remain meaningful across the full continuum of care. The most impactful advances are no longer just the therapies themselves, but the infrastructure that delivers them equitably:
- Navigation programs to guide patients through life after cancer
- Dedicated survivorship clinics and community-based follow-up models
- Digital tools that help survivors monitor symptoms and stay connected to their care teams
- Workforce training and multidisciplinary care coordination
Survivorship support does not begin and end with healthcare systems alone. Organizations such as the American Cancer Society play a critical role by providing trusted information, support services, transportation and lodging assistance, and survivorship resources that help patients navigate life beyond treatment. These programs help translate advances in cancer care into meaningful support for survivors and their families in the communities where they live.
At STO, we believe improving cancer outcomes requires more than scientific discovery alone. It requires building systems capable of delivering that progress sustainably across all care settings.
In this year’s National Cancer Survivors Month, survivorship should not be viewed as the finish line of the cancer journey. It must be recognized as one of oncology’s next major implementation priorities.
Because the future of oncology will be measured not only by survival, but by how well people are able to live beyond cancer.